CROI 2013: Advances in Hepatitis C Treatment 2013 [VIDEO]

The advent of direct-acting antiviral agents targeting hepatitis C virus (HCV) have brought about a new era of treatment, but many questions remain about how these new medications will be used in real-world clinical practice.

[Produced in collaboration with IFARA]

In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Marks from Weill Cornell Medical Center spoke with Liz Highleyman of HIVandHepatitis.com about implications of new therapies for hepatitis C patients and providers.

Read more:

Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo

Presidio Pharmaceuticals and Boehringer Ingelheim will jointly conduct a Phase 2a trial to evaluate an all-oral combination containing its NS4A inhibitor PPI-668 plus faldaprevir and BI 207127, with or without ribavirin, for people with hard-to-treat genotype 1a hepatitis C virus.

Read more:

CROI 2013: New Treatments for Hepatitis C and HIV/HCV Coinfection

New treatments for hepatitis C were a key focus at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) this month in Atlanta. Researchers described several next-generation direct-acting antiviral agents for both HCV monoinfected and HV/HCV coinfected people, as well as some interferon-free regimens.

Read more:

CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men

Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of therapy and improves the likelihood of a cure for HIV positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

Read more:

CROI 2013: Sofosbuvir + Ribavirin Works Well for Inner-City Hepatitis C Patients

A simple 24-week, all-oral regimen of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 chronic hepatitis C, many of whom had factors predictive of poor response, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

Read more:

CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected

Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

Read more:

CROI 2013: AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients

All-oral regimens containing the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor, and ribavirin led to sustained response for more than 90% of previously untreated patients -- including those with unfavorable IL28B gene patterns -- but only about half of prior non-responders, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

Read more:

CROI 2013: Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]

Adding telaprevir (Incivek) to pegylated interferon/ribavirin for treating HIV positive men with acute sexually transmitted hepatitis C considerably shortens the duration of therapy and improves the likelihood of a cure, according to study findings presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

Read more: